AbbVie (ABBV) Given New $98.10 Price Target at Credit Suisse Group

AbbVie (NYSE:ABBV) had its price objective decreased by Credit Suisse Group from $109.00 to $98.10 in a research report sent to investors on Friday morning. Credit Suisse Group currently has a neutral rating on the stock.

ABBV has been the topic of a number of other reports. Argus raised their target price on shares of AbbVie from $120.00 to $145.00 and gave the stock a buy rating in a research report on Friday, February 2nd. Zacks Investment Research lowered shares of AbbVie from a buy rating to a hold rating in a report on Tuesday. BMO Capital Markets lowered shares of AbbVie from a market perform rating to an underperform rating and cut their price objective for the company from $125.86 to $84.00 in a report on Monday, January 29th. They noted that the move was a valuation call. Piper Jaffray Companies lifted their price objective on shares of AbbVie from $130.00 to $138.00 and gave the company an overweight rating in a report on Thursday, February 15th. Finally, Evercore ISI reissued a buy rating and set a $144.00 price objective on shares of AbbVie in a report on Monday, January 29th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. AbbVie has a consensus rating of Buy and an average price target of $116.47.

How to Become a New Pot Stock Millionaire

Shares of AbbVie (NYSE ABBV) traded down $0.64 during trading hours on Friday, hitting $97.46. 14,252,728 shares of the stock were exchanged, compared to its average volume of 6,580,511. The stock has a market capitalization of $155,780.16, a price-to-earnings ratio of 29.62, a PEG ratio of 0.93 and a beta of 1.52. AbbVie has a fifty-two week low of $63.12 and a fifty-two week high of $125.86. The company has a current ratio of 1.28, a quick ratio of 1.18 and a debt-to-equity ratio of 6.07.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, topping the Zacks’ consensus estimate of $1.44 by $0.04. The business had revenue of $7.74 billion for the quarter, compared to analyst estimates of $7.53 billion. AbbVie had a net margin of 18.82% and a return on equity of 158.15%. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period last year, the company posted $1.20 earnings per share. sell-side analysts expect that AbbVie will post 7.47 EPS for the current fiscal year.

AbbVie declared that its board has initiated a stock buyback program on Thursday, February 15th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be issued a $0.96 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $0.71. This represents a $3.84 annualized dividend and a yield of 3.94%. The ex-dividend date of this dividend is Thursday, April 12th. AbbVie’s payout ratio is currently 86.32%.

In other news, insider Laura J. Schumacher sold 25,000 shares of AbbVie stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $117.85, for a total transaction of $2,946,250.00. Following the completion of the sale, the insider now directly owns 123,317 shares in the company, valued at $14,532,908.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Robert A. Michael sold 992 shares of AbbVie stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $120.31, for a total transaction of $119,347.52. The disclosure for this sale can be found here. Insiders sold 211,197 shares of company stock worth $24,585,575 over the last ninety days. Corporate insiders own 0.23% of the company’s stock.

Several large investors have recently bought and sold shares of ABBV. Bristlecone Advisors LLC acquired a new position in AbbVie during the third quarter valued at $113,000. Truewealth LLC acquired a new position in AbbVie during the fourth quarter valued at $126,000. Delpha Capital Management LLC acquired a new position in AbbVie during the fourth quarter valued at $131,000. Virtue Capital Management LLC acquired a new position in AbbVie during the fourth quarter valued at $139,000. Finally, We Are One Seven LLC acquired a new position in AbbVie during the fourth quarter valued at $148,000. Institutional investors and hedge funds own 70.51% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3296039/abbvie-abbv-given-new-98-10-price-target-at-credit-suisse-group.html.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Lions Gate Entertainment  Receives Media Impact Score of 0.14
Lions Gate Entertainment Receives Media Impact Score of 0.14
Somewhat Positive Media Coverage Somewhat Unlikely to Affect First Hawaiian Bank  Share Price
Somewhat Positive Media Coverage Somewhat Unlikely to Affect First Hawaiian Bank Share Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cree  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cree Stock Price
Wedbush Reaffirms “Outperform” Rating for Steve Madden
Wedbush Reaffirms “Outperform” Rating for Steve Madden
Catasys  Rating Lowered to Strong Sell at Zacks Investment Research
Catasys Rating Lowered to Strong Sell at Zacks Investment Research
Robert W. Baird Reiterates Buy Rating for TSYS
Robert W. Baird Reiterates Buy Rating for TSYS


© 2006-2018 Ticker Report. Google+.